Table 1. Demographic Information at Baseline.
| Intervention | Placebo | GnRHa | p-value |
|---|---|---|---|
| N | 29 | 29 | 1 |
| 5-HTTLPR | 10/19 | 10/19 | 1 |
| Age (years) | 25.4±6.0 | 23.2±3.0 | 0.08 |
| Body mass index | 23.4±3.9 | 23.2±2.4 | 0.80 |
| Neuroticism | 86.6±22.1 | 86.5±21.0 | 0.99 |
| HDRS-17 | 1.6±2.2 | 1.2±1.6 | 0.46 |
| PSS | 9.7±5.7 | 9.4±4.6 | 0.82 |
| PMSQ | 7.6±6.2 | 6.6±4.7 | 0.48 |
| Cycle length (days) | 28.8±3.8 | 30.6±3.9 | 0.08 |
| FSH | 5.7±2.2 | 6.2±1.9 | 0.36 |
| Estradiol | 0.19±0.11 | 0.19±0.10 | 0.97 |
| Progesterone | 1.7±0.7 | 2.7±5.2 | 0.35 |
| Antral follicle count | 28.4±14.4 | 26.2±10.7 | 0.52 |
Values expressed as mean±SD; 5-HTTLPR indicates LALA/S'-carriers; neuroticism score from NEO PI-R; HDRS-17, Hamilton Depression Rating Scale-17 score; PSS, perceived stress score; PMSQ, premenstrual symptoms questionnaire score; FSH, follicle-stimulating hormone measured at cycle days 2–5 during screening procedures; Antral follicle count, assessed by ultrasound examination of the ovaries. p-value reflects χ2-test or two-sample t-test for differences between groups.